10-Q · May 15, 2026
Enveric Biosciences reported no revenue for Q4 2025, with a diluted EPS of -0.5, which is a significant improvement from previous periods; however, the company continues to face considerable losses. Operating expenses…
Earnings analysis · 10-Q
ENVB earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Enveric’s diluted loss improved substantially to $0.76 per share from $11.65 year over year, but net loss increased to $3.0 million from $2.5 million. The company raised approximately $6.5 million and held $8.3 million…
Read full summary
Enveric’s diluted loss improved substantially to $0.76 per share from $11.65 year over year, but net loss increased to $3.0 million from $2.5 million. The company raised approximately $6.5 million and held $8.3 million in cash while continuing to advance EB-003 toward an IND and Phase 1 trial. Persistent losses, unresolved control weaknesses, financing needs, and potential Nasdaq compliance pressure keep the overall outlook mixed.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.76
What stood out
-
Diluted loss improved year over year
Diluted loss improved to $0.76 per share in Q2 2026 from $11.65 per share in Q2 2025, although the company remained loss-making.
-
Raised $6.5 million during the quarter
The company raised approximately $6.5 million during the quarter and reported $8.3 million of cash, supporting near-term development activities.
-
EB-003 advanced toward Phase 1
Enveric continued advancing EB-003 toward an IND application and Phase 1 trial, maintaining its stated development plan.
-
Control weaknesses remain unresolved
Management concluded that disclosure controls were not effective as of June 30, 2026, reflecting previously identified material weaknesses in internal control over financial reporting.
What to watch
-
Persistent operating losses
The company reported a $3.0 million net loss for Q2 2026 versus a $2.5 million net loss in the prior-year quarter, indicating continued operating losses despite the improvement in per-share loss.
-
Financing and cash-burn risk
Reported cash was $8.3 million after raising approximately $6.5 million during the quarter, leaving ongoing dependence on additional financing to fund development and operations.
-
Potential Nasdaq delisting risk
Nasdaq’s approved continued-listing requirement generally requires market value of listed securities of at least $5 million. The company stated its MVLS had recently been near that threshold, creating potential delisting risk if the rule becomes operative.
Management's outlook
No numeric revenue or EPS guidance was provided. Management reiterated plans to complete IND-enabling activities, submit an IND application, and advance EB-003 into a Phase 1 trial.
Earlier filings 4
10-K · March 27, 2026
Enveric remains a pre-revenue, R&D-stage biotech focused on its lead neuroplastogen EB-003 (EVM301 Series), which has completed short-term dose-range finding toxicology and is "ready to advance into IND-enabling, GLP…
10-Q · August 14, 2025
Enveric reported no revenue and a Q2 2025 net loss of $2,519,181 (EPS $(0.97)) vs. a Q2 2024 net loss of $1,879,394 (EPS $(3.72)); operating expenses rose to $2,519,049 from $1,897,931 driven by R&D growth. Cash…
10-Q · May 15, 2024
Enveric reported a narrower net loss of $(2,456,915) for the three months ended March 31, 2024 versus a net loss attributable to shareholders of $(4,800,847) in the prior year period, and EPS improved to $(0.61) from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.